OVARIAN MUCINOUS CYSTADENOCARCINOMA
Clinical trials for OVARIAN MUCINOUS CYSTADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN MUCINOUS CYSTADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN MUCINOUS CYSTADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat ovarian cancer: drug combo shows promise
Disease control OngoingThis study tests whether adding a drug called AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has returned and is resistant to platinum-based treatments. About 124 women will be randomly assigned to receive either…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
Ovarian cancer study tests which chemo combo works best
Disease control OngoingThis study compares two chemotherapy regimens (carboplatin+paclitaxel vs oxaliplatin+capecitabine), with or without the drug bevacizumab, as first treatment for mucinous ovarian or fallopian tube cancer. About 50 participants with newly diagnosed or recurrent disease are enrolled…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:43 UTC
-
New drug duo targets Hard-to-Treat brain tumors
Disease control OngoingThis early-phase trial tests a new drug (MLN0128) combined with bevacizumab in people with recurrent glioblastoma (a brain cancer) or other advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand side ef…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:50 UTC